TREA

86879881 - GLOBOVAX

Follow

Information

  • Trademark
  • 86879881
  • Serial Number
    86879881
  • Filing Date
    January 19, 2016
    9 years ago
  • Transaction Date
    June 12, 2018
    6 years ago
  • Status Date
    June 12, 2018
    6 years ago
  • Published for Opposition Date
    September 06, 2016
    8 years ago
  • Location Date
    June 12, 2018
    6 years ago
  • Status Code
    602
  • Current Location
    TMEG LAW OFFICE 108 - EXAMINING ATTORNEY ASSIGNED
    Employee Name
    HACK, ANDREA R
  • Attorney Docket Number
    FORMO-02400
    Attorney Name
    Jonathan O. Owens
    Law Office Assigned Location Code
    L80
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
GLOBOVAX
Case File Statements
  • GS0051: adjuvants for medical purposes; amino acids for medical purposes; amino acids for veterinary purposes; soap-bark tree, quillaja, quillais and Quillaja saponaria Molina barks for pharmaceutical purposes; biological preparations for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; biological preparations for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; chemical reagents for medical or veterinary purposes; chemical preparations for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemical preparations for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemical preparations for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemico-pharmaceutical preparations for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; drugs for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; glucose for medical purposes; milk sugar for pharmaceutical purposes; lactose for pharmaceutical purposes; medicinal roots; medicinal herbs; medicinal oils; medicinal infusions for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; medicines for human purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; medicines for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; pharmaceutical preparations for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; phosphates for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; potassium salts for medical purposes; reagent paper for medical or veterinary purposes; mineral salts for medical purposes; sodium salts for medical purposes; sugar for medical purposes; vaccines; veterinary preparations for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; yeast for pharmaceutical purposes; acetates for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; acids for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; alginates for pharmaceutical purposes; blood for medical purposes; blood plasma; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; diastase for medical purposes; enzyme preparations for medical purposes; enzymes for medical purposes; ferments for pharmaceutical purposes; medicated pastilles for pharmaceutical purposes; medicated lozenges for pharmaceutical purposes; flour for pharmaceutical purposes; meal for pharmaceutical purposes; hormones for medical purposes; milk ferments for pharmaceutical purposes; cultures of microorganisms for medical and veterinary use; preparations of microorganisms for medical and veterinary use, namely, nutritive substances for microorganisms for medical and veterinary use; serotherapeutic medicines for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; medicated serums for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; stem cells for medical purposes; anti-cancer preparations; adjuvants for use with vaccines; biological preparations for the treatment of cancer. drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; ferments for medical or veterinary use; human vaccine preparations; medicinal preparations for the treatment of infectious diseases and for use in oncology; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; reagents for medical use; vaccine adjuvants; vaccine preparations; vaccine stabilizers
  • PM0001: GLOBALL VAX
Case File Event Statements
  • 6/12/2018 - 6 years ago
    38 - ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Type: MAB2
  • 6/12/2018 - 6 years ago
    37 - ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Type: ABN2
  • 2/20/2018 - 7 years ago
    36 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/14/2017 - 7 years ago
    35 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 11/14/2017 - 7 years ago
    34 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 11/14/2017 - 7 years ago
    33 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 11/14/2017 - 7 years ago
    32 - CASE RETURNED TO EXAMINATION Type: OTHE
  • 10/27/2017 - 7 years ago
    31 - NOTICE OF ALLOWANCE CANCELLED Type: IUCN
  • 11/14/2017 - 7 years ago
    30 - PREVIOUS ALLOWANCE COUNT WITHDRAWN Type: ZZZX
  • 11/2/2017 - 7 years ago
    29 - ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED Type: ATRQ
  • 11/2/2017 - 7 years ago
    28 - PETITION TO DIRECTOR - CHANGE BASIS - GRANTED Type: PCBG
  • 10/31/2017 - 7 years ago
    27 - ASSIGNED TO PETITION STAFF Type: APET
  • 10/31/2017 - 7 years ago
    26 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 10/27/2017 - 7 years ago
    25 - EXTENSION 2 GRANTED Type: EX2G
  • 10/27/2017 - 7 years ago
    24 - EXTENSION 2 FILED Type: EXT2
  • 10/27/2017 - 7 years ago
    23 - TEAS EXTENSION RECEIVED Type: EEXT
  • 10/9/2017 - 7 years ago
    22 - TEAS PETITION TO AMEND BASIS RECEIVED Type: TPAD
  • 3/14/2017 - 7 years ago
    21 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 3/10/2017 - 8 years ago
    20 - EXTENSION 1 GRANTED Type: EX1G
  • 3/10/2017 - 8 years ago
    19 - EXTENSION 1 FILED Type: EXT1
  • 3/10/2017 - 8 years ago
    18 - TEAS EXTENSION RECEIVED Type: EEXT
  • 11/1/2016 - 8 years ago
    17 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 9/6/2016 - 8 years ago
    16 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 9/6/2016 - 8 years ago
    15 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 8/17/2016 - 8 years ago
    14 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 8/3/2016 - 8 years ago
    13 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV
  • 8/2/2016 - 8 years ago
    12 - ASSIGNED TO LIE Type: ALIE
  • 7/21/2016 - 8 years ago
    11 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 7/15/2016 - 8 years ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 7/14/2016 - 8 years ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/14/2016 - 8 years ago
    8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 2/8/2016 - 9 years ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 2/8/2016 - 9 years ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 2/8/2016 - 9 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 2/8/2016 - 9 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 1/26/2016 - 9 years ago
    3 - NOTICE OF PSEUDO MARK E-MAILED Type: MPMK
  • 1/25/2016 - 9 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 1/22/2016 - 9 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP